TIKOSYN

SECTION 2: Hazards identification

Appearance: 0.125 mg - Orange/white capsules 0.25 mg - Peach capsules 0.50 mg - Peach/white capsules

Hazard statements

Non-hazardous in accordance with international standards for workplace safety.

Additional information

Short Term: Dust may cause transient irritation . (based on animal data) . Accidental ingestion may cause effects similar to those seen in clinical use. Drugs of this class have been associated with rare, but potentially serious cardiac events. These events have not been observed from occupational exposures, however, those with preexisting cardiovascular illnesses may be at increased risk from exposure. Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on testes and the developing fetus. Known Clinical Effects: The most frequent adverse effects seen during clinical use are headache, chest pain, and dizziness.

EU Classification

EU Indication of danger: Not classified Australian Hazard Classification Non-Hazardous Substance. Non-Dangerous Goods. (NOHSC): Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.